ID   PER.C6
AC   CVCL_G704
SY   Per.C6; PER C6; PERC6; PerC6; Perc6; PER cell clone 6
DR   FCS-free; 39-13-46-1-8-11
DR   Wikidata; Q54947225
RX   Patent=US6602706;
RX   Patent=US9469865;
RX   PubMed=9741429;
RX   PubMed=11257414;
RX   PubMed=16566444;
RX   PubMed=18052336;
RX   PubMed=25903999;
RX   PubMed=28450423;
WW   https://web.archive.org/web/20140721200546/http://www.crucell.com/page/downloads/Factsheet_PER.C6_Technology.pdf
WW   https://web.archive.org/web/20121219090924/http://www.dsm.com/en_US/downloads/dpp/PER.C6_Brochure.pdf
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/p/cell-lines-detail-452.html
CC   Group: Patented cell line.
CC   Group: Vaccine production cell line.
CC   From: Johnson & Johnson Janssen (originally Crucell).
CC   Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 96022940.
CC   Biotechnology: Used for the production of follitropin delta (Trade name: Rekovelle).
CC   Transformant: NCBI_TaxID; 28285; Adenovirus 5 [E1A/E1B].
CC   Misspelling: Per.Co6; Occasionally.
CC   Derived from sampling site: Fetal eye; retina. Cell type=Retinoblast.
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_1K15 ! 911
SX   Sex unspecified
AG   18FW
CA   Transformed cell line
DT   Created: 11-02-13; Last updated: 16-12-21; Version: 19
//
RX   Patent=US6602706;
RA   Fallaux F.J., Hoeben R.C., van der Eb A.J., Bout A., Valerio D.;
RT   "Packaging systems for human recombinant adenovirus to be used in gene
RT   therapy.";
RL   Patent number US6602706, 05-Aug-2003.
//
RX   Patent=US9469865;
RA   Zijlstra G.M., Hof R.P., Schilder J.;
RT   "Process for the culturing of cells.";
RL   Patent number US9469865, 18-Oct-2016.
//
RX   PubMed=9741429; DOI=10.1089/hum.1998.9.13-1909;
RA   Fallaux F.J., Bout A., van der Velde I., van den Wollenberg D.J.M.,
RA   Hehir K.M., Keegan J., Auger C., Cramer S.J., van Ormondt H.,
RA   van der Eb A.J., Valerio D., Hoeben R.C.;
RT   "New helper cells and matched early region 1-deleted adenovirus
RT   vectors prevent generation of replication-competent adenoviruses.";
RL   Hum. Gene Ther. 9:1909-1917(1998).
//
RX   PubMed=11257414; DOI=10.1016/S0264-410X(00)00508-9;
RA   Pau M.G., Ophorst C., Koldijk M.H., Schouten G., Mehtali M.,
RA   Uytdehaag F.;
RT   "The human cell line PER.C6 provides a new manufacturing system for
RT   the production of influenza vaccines.";
RL   Vaccine 19:2716-2721(2001).
//
RX   PubMed=16566444;
RA   Lewis J.A., Brown E.L., Duncan P.A.;
RT   "Approaches to the release of a master cell bank of PER.C6 cells; a
RT   novel cell substrate for the manufacture of human vaccines.";
RL   Dev. Biol. (Basel) 123:165-176(2006).
//
RX   PubMed=18052336; DOI=10.1021/bp070258u;
RA   Berdichevsky M., Gentile M.-P., Hughes B., Meis P., Peltier J.,
RA   Blumentals I., Aunins J., Altaras N.E.;
RT   "Establishment of higher passage PER.C6 cells for adenovirus
RT   manufacture.";
RL   Biotechnol. Prog. 24:158-165(2008).
//
RX   PubMed=25903999; DOI=10.1002/biot.201400388;
RA   Genzel Y.;
RT   "Designing cell lines for viral vaccine production: where do we
RT   stand?";
RL   Biotechnol. J. 10:728-740(2015).
//
RX   PubMed=28450423; DOI=10.1530/EC-17-0067;
RA   Koechling W., Plaksin D., Croston G.E., Jeppesen J.V., Macklon K.T.,
RA   Andersen C.Y.;
RT   "Comparative pharmacology of a new recombinant FSH expressed by a
RT   human cell line.";
RL   Endocr. Connect. 6:297-305(2017).
//